Palacionyte, J.; Januskevicius, A.; Vasyle, E.; Rimkunas, A.; Miliauskas, S.; Malakauskas, K.
Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma. Diagnostics 2024, 14, 1345.
https://doi.org/10.3390/diagnostics14131345
AMA Style
Palacionyte J, Januskevicius A, Vasyle E, Rimkunas A, Miliauskas S, Malakauskas K.
Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma. Diagnostics. 2024; 14(13):1345.
https://doi.org/10.3390/diagnostics14131345
Chicago/Turabian Style
Palacionyte, Jolita, Andrius Januskevicius, Egle Vasyle, Airidas Rimkunas, Skaidrius Miliauskas, and Kestutis Malakauskas.
2024. "Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma" Diagnostics 14, no. 13: 1345.
https://doi.org/10.3390/diagnostics14131345
APA Style
Palacionyte, J., Januskevicius, A., Vasyle, E., Rimkunas, A., Miliauskas, S., & Malakauskas, K.
(2024). Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma. Diagnostics, 14(13), 1345.
https://doi.org/10.3390/diagnostics14131345